DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Effect of statin therapy on disease progression in pediatric ADPKD: design and baseline characteristics of participants.

Author(s): Cadnapaphornchai MA, George DM, Masoumi A, McFann K, Strain JD, Schrier RW

Affiliation(s): Department of Medicine, University of Colorado Denver, Aurora, CO, USA. Melissa.Cadnapaphornchai@ucdenver.edu

Publication date & source: 2011-05, Contemp Clin Trials., 32(3):437-45. Epub 2011 Jan 23.

Publication type: Clinical Trial, Phase III; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney condition and is associated with important renal and cardiovascular manifestations in childhood. Renal cystic disease can be documented in some cases as early as in utero. Early intervention is critical if the long-term complications of this condition, including end-stage renal disease, are to be ameliorated. Here we describe our ongoing randomized double-blind placebo-controlled phase III clinical trial to assess the effect of pravastatin treatment on renal and cardiovascular disease progression in 107 children and young adults age 8-22 years with ADPKD who are receiving the angiotensin converting enzyme inhibitor lisinopril. Baseline demographic and laboratory data are provided. Results of this study could markedly impact the standard of care for evaluation and treatment of ADPKD in this population. Copyright (c) 2011 Elsevier Inc. All rights reserved.

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017